EscharEx Trials And Aging Populations Will Expand Wound Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
10 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$39.00
54.9% undervalued intrinsic discount21 Aug
US$17.61
1Y
-5.1%7D
-2.7%